Table 1. Baseline characteristics.
| Characteristics | TCbHP group (n=46) | THP group (n=26) | P value |
|---|---|---|---|
| Age at diagnosis/years | |||
| Mean ± standard deviation | 48.66±9.55 | 59.31±9.28 | <0.001 |
| Median [range] | 51 [32–63] | 57 [45–76] | |
| EGOC score | 0.063 | ||
| 0 | 43 | 20 | |
| 1 | 3 | 6 | |
| Menopausal status | <0.001 | ||
| Premenpause | 30 | 3 | |
| Postmenopause | 16 | 23 | |
| Clinical T classificationa | 0.358 | ||
| T1 | 5 | 7 | |
| T2 | 30 | 13 | |
| T3 | 9 | 5 | |
| T4 | 2 | 1 | |
| Clinical N classificationa | 0.063 | ||
| N1 | 15 | 3 | |
| N2 | 16 | 8 | |
| N3 | 15 | 15 | |
| AJCC stagea | 0.136 | ||
| II A | 0 | 0 | |
| II B | 15 | 3 | |
| III A | 14 | 7 | |
| III B | 2 | 1 | |
| III C | 15 | 15 | |
| Histology | 1.0 | ||
| Invasive ductal | 44 | 25 | |
| Others | 2 | 1 | |
| ER status | 0.623 | ||
| Positive | 18 | 12 | |
| Negative | 28 | 14 | |
| PR status | 0.314 | ||
| Positive | 15 | 12 | |
| Negative | 31 | 14 | |
| Immunohistochemical HER2 status | 1.0 | ||
| IHC 2+ | 8 | 4 | |
| IHC 3+ | 38 | 22 | |
| Ki67 index | 0.517 | ||
| ≥30 | 37 | 23 | |
| <30 | 9 | 3 | |
| Chemotherapy cycles | NA | ||
| 6 | 46 | 26 | |
| Others | 0 | 0 | |
| RECIST-based treatment response | 0.891 | ||
| CR | 10 | 6 | |
| PR | 33 | 19 | |
| SD | 3 | 1 | |
| PD | 0 | 0 | |
| Surgery methods | 1.0 | ||
| Mastectomy | 40 | 23 | |
| BCS | 6 | 3 |
aClinical tumor size and nodal status were assessed according to the 8th edition of the American Joint Committee on Cancer TNM staging system. ECOG, Eastern Cooperative Oncology Group; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; BCS, breast-conserving surgery.